BiSuperTM-GalNAc platform

BiSuper^TM-GalNAc Platform Introduction

The liver targeted delivery technology of small nucleic acid drugs based on GalNAc ligands is currently one of the main supporting platforms for the development of oligonucleotides drugs, and about one-third of the small nucleic acid drugs in the global research and development pipeline are based on this technology.

BiSuper^TM-GalNAc is a small nucleic acid liver targeted delivery technology independently developed by Biosyntech, which has high delivery efficiency and long-lasting efficacy (as shown in the following figure for in vivo and in vitro delivery evaluation analysis), and also has the characteristics of low cost and easy amplification. The BiSuperTM GalNAc platform collaborates with customers through various modes such as authorization to accelerate the development process of small nucleic acid drugs.

                    In vitro delivery evaluation analysis chart                                                                      In vivo delivery evaluation analysis chart